Dermatology Department, Faculty of Medicine, Ondokuz Mayıs University, Samsun 55139, Turkey.
Medicina (Kaunas). 2020 Mar 3;56(3):107. doi: 10.3390/medicina56030107.
: Demodex species are common obligatory parasites and normally present in low number in human beings. Immunosuppression was suggested to be associated with increased density of Demodex mites. Systemic glucocorticoids, cyclosporine, methotrexate, and azathioprine are commonly used immunosuppressive agents. We aim to determine the pre- and post-treatment Demodex densities in patients receiving immunosuppressive therapy and compare with those of healthy subjects. : Demodex density was investigated at the beginning, first, and third months of the immunosuppressive therapy in 45 patients who received methotrexate, cyclosporine, systemic steroid, or azathioprine treatments and in 45 healthy subjects at the same time as the patients. Five standardized skin surface biopsies were taken from cheeks, forehead, nose, and chin of the patients and control group. The presence of five or more parasites in 1 cm area was considered as positive. : Demodex test was negative at the beginning of the treatment in all patients. Demodex test was positive in one patient in the first and third months of treatment and in three patients only in the third month of treatment. In the control group, Demodex test was determined as positive in just one healthy individual at the beginning, first and third months of the study. When the patient and control groups were evaluated in terms of Demodex number, there was a statistically significant difference in Demodex density in patients treated with immunosuppressive treatment in the first and third months when compared with the control group ( < 0.05). : Immunosuppressive treatment might increase the number of Demodex mites and demodicidosis should be kept in mind in patients on immunosuppressive treatment.
: 蠕形螨是常见的专性寄生虫,通常在人类中数量较低。免疫抑制被认为与蠕形螨密度增加有关。系统性糖皮质激素、环孢素、甲氨蝶呤和硫唑嘌呤是常用的免疫抑制剂。我们旨在确定接受免疫抑制治疗的患者在治疗前和治疗后的蠕形螨密度,并与健康受试者进行比较。: 在接受甲氨蝶呤、环孢素、全身类固醇或硫唑嘌呤治疗的 45 名患者和同时接受治疗的 45 名健康受试者中,在免疫抑制治疗开始、第一个月和第三个月时,研究了蠕形螨密度。从患者和对照组的脸颊、额头、鼻子和下巴处采集了 5 个标准化的皮肤表面活检。如果在 1 cm 面积内发现 5 个或更多寄生虫,则认为检测结果为阳性。: 在治疗开始时,所有患者的蠕形螨检测均为阴性。在治疗的第一个和第三个月,有 1 名患者的蠕形螨检测为阳性,仅在第三个月有 3 名患者的检测为阳性。在对照组中,在研究的开始、第一个月和第三个月,只有 1 名健康个体的蠕形螨检测为阳性。当根据患者和对照组的蠕形螨数量进行评估时,与对照组相比,接受免疫抑制治疗的患者在治疗的第一个和第三个月时,蠕形螨密度存在统计学显著差异(<0.05)。: 免疫抑制治疗可能会增加蠕形螨的数量,因此在接受免疫抑制治疗的患者中应注意蠕形螨病。